Hematology News

The FDA approved lusutrombopag for the treatment of thrombocytopenia among adults with chronic liver disease who are scheduled to undergo a medical or dental procedure.

IV immunoglobin treatment at immune thrombocytopenia diagnosis did not lead to a lower rate of chronic immune thrombocytopenia among children, according to results from a randomized clinical trial.

Patients who underwent blood or marrow transplantation during childhood remained at greater risk for death up to 25 years later compared with the general population, according to a study published in JAMA Oncology.

The use of thawed plasma during prehospital air medical transport appeared safe and led to lower 30-day mortality than standard resuscitation among patients at risk for severe hemorrhage, according to results from the phase 3 Prehospital Air Medical Plasma, or PAMPer, clinical trial.

Unrelated cord blood transplantation served as a valuable curative option for patients with refractory severe aplastic anemia who had no matched related donors, according to findings from a phase 2 study.

Adults and children with sickle cell disease who received prescription-grade oral L-glutamine alone or with hydroxyurea experienced fewer painful sickle cell crises than patients who received placebo, according to phase 3 study results published in The New England Journal of Medicine.

A clinical prediction model that used tumor-site category and D-dimer as the only variables accurately predicted risk for venous thromboembolism among patients with solid cancers seen outside the hospital setting, according to findings published in The Lancet Haematology.

Venous thromboembolism incidence appeared high among patients with solid tumors who had implanted ports, according to study results.

Patients with venous thromboembolism and a contraindication to anticoagulation who received an inferior vena cava filter had a significantly increased risk for 30-day mortality after adjustment for various factors, including immortal time bias, according to recently published data.

A randomized phase 3 trial designed to evaluate luspatercept for adults with transfusion-dependent beta-thalassemia achieved its primary and key secondary endpoints, according to the agent’s manufacturers.